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In this issue of Cancer Cell, Woolston et al. show that colorectal cancers that become 
refractory to initially effective anti-EGFR therapy, besides harboring resistance-conferring 
mutations, also contain abundant stromal and immune cells. This phenotypic 
reconfiguration has functional relevance and puts forward therapeutic opportunities for 
patients who relapse on EGFR-targeting treatment.  
 
The EGFR antibodies cetuximab and panitumumab are used in patients with KRAS or NRAS wild-
type metastatic colorectal cancer (mCRC) either in combination with standard chemotherapy, for 
first-line treatment, or as single agents when tumors become resistant to prior cytotoxic regimens. 
However, only 20% of individuals experience tumor regressions, and only an additional 30% have 
some extent of clinical benefit in terms of disease stabilization (Douillard et al., 2013). This relatively 
low response rate is compounded by the dismal reality that subjects who initially respond typically 
become refractory to treatment in a period of months. In this issue of Cancer Cell, Woolston et al. 
(2019) offer a comprehensive picture of the identifying traits of primary and acquired resistance to 
cetuximab in a clinical cohort of 35 mCRC patients (Figure 1). Different from previous studies, 
mostly conducted in a retrospective manner and focused on a small number of candidate 
biomarkers, here the authors embarked on a prospective trial whereby biopsies collected before 
initiation of single-agent cetuximab and at the time of disease progression were subjected to whole 
exome and RNA sequencing analyses and immunophenotyping. 
 Lack of response to antibody treatment ab initio has been partly ascribed to the occurrence of 
mutations or amplifications in genes encoding other tyrosine kinase receptors or RAS downstream 
effectors, which, similar to mutationally activated RAS, trigger compensatory pathways sustaining 
EGFR-independent tumor growth (Bertotti et al., 2015). Since these genetic abnormalities occur 
individually at very low frequency, their catalog has not yet saturated the space of mCRC tumors 
with primary resistance to EGFR antibodies. Indeed, when the authors stratified global genomic 
data onto response annotation, they pinpointed previously unrecognized alterations, including 
biallelic inactivation of NF1 (a GTPase-activating protein that antagonizes RAS function) and KRAS 
and BRAF mutations endowed with attenuated enzymatic and transforming activity. Interestingly, 
hypomorphic BRAF and KRAS mutations co-existed in the same tumor or, when present singly, 
were associated with polysomy of the corresponding chromosome, suggesting that their individual 
contribution to cetuximab resistance is suboptimal and requires either a cooperative or a dosage 
effect for complete manifestation. 
 Secondary resistance is often propelled by the clonal expansion of the same alterations 
responsible for primary resistance, with a preponderance of RAS pathway mutations. Such 
alterations may arise de novo on a stochastic basis, as a consequence of tumor genetic instability, 
or may pre-exist as minor subclones in the original tumor population because of genetic 
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heterogeneity and become positively selected under drug pressure (Khan et al., 2018). Genetic 
instability and heterogeneity explain why acquired resistance mutations are usually polyclonal and 
can be more accurately grasped by analysis of circulating tumor DNA (ctDNA) – which incorporates 
DNA fragments shed by the whole tumor – than by examination of solid biopsies – which, by 
definition, are subspatial snapshots of the entire lesion (Khan et al., 2018). Woolston et al. (2019) 
report a number of genetic alterations of acquired resistance, including already characterized 
mutations in components of the RAS pathway (Khan et al., 2018) and a hitherto unidentified 
amplification of FGF10 (encoding a ligand of the FGFR2 tyrosine kinase receptor). These genetic 
aberrations were detected in only a limited number of post-treatment biopsies but were mostly 
captured in ctDNA samples, further attesting to the pervasiveness of tissue sampling bias. Of note, 
ctDNA resistance mutations were calculated to occur in a minority of cells, in keeping with previous 
reports demonstrating the presence of recurrent but subclonal RAS pathway mutations in the blood 
of cetuximab-refractory mCRC patients (Bettegowda et al., 2014; Khan et al., 2018). Altogether, 
these findings suggest that tumor relapse is engendered by polyclonal mutuality, with an ecosystem 
of different subclones contributing to therapeutic resistance. However, we cannot exclude that when 
subclonal alterations are present at a very low allele frequency the impact on resistance may 
remain sub-threshold, and other (non-genetic) determinants could subsidize DNA mutations to 
reduce responsiveness to EGFR inhibition. 
 Woolston et al. (2019) strongly embrace the assumption that progression on cetuximab can be 
also fostered by non-mutational mechanisms and extend their investigation by delineating the 
transcriptomic profiles of matched sensitive and post-therapy resistant tumors. First, they confirm 
that a subgroup of tumors with gene expression traits reminiscent of those portrayed by the 
transient-amplifying precursors of the normal intestine (assigned to the so-called CMS2 consensus 
transcriptional subtype) were enriched for cetuximab-responsive cases. Then, the authors show that 
the majority of tumors with acquired resistance to cetuximab (including some harboring subclonal 
mutations) underwent a gene expression transition towards a stroma-rich (CMS4) phenotype 
featuring high content of carcinoma-associated fibroblasts (CAFs) and increased expression of 
CAF-derived growth factors such as TGF, HGF, and FGF family ligands. Consistent with the 
observed association between stromal abundance and drug resistance, the CAF secretome was 
found to exert a protective activity against cetuximab. These results highlight a key role for 
transcriptionally regulated growth factors in conveying survival cues that safeguard CRC tumors 
from the effects of EGFR blockade, in agreement with previous findings (Zanella et al., 2015).  
 Intriguingly, Woolston et al. (2009) describe a more copious representation of cytotoxic T 
lymphocytes and dendritic cells, increased expression of a T cell-associated inflammatory 
signature, and upregulation of immune checkpoints in CMS4-like, TGF-high resistant tumors. This 
result corroborates a retrospective study documenting heightened infiltration of cytotoxic, effector 
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memory, and regulatory T cells in CRC tumors treated with cetuximab and chemotherapy (Van den 
Eynde et al., 2018). However, the coexistence of elevated TGF activity and immune inflammation 
is unexpected, as TGFβ is known to impair T cell function and promote T cell physical exclusion 
(Tauriello et al., 2018). How can cetuximab-resistant tumors concomitantly display high levels of 
immune suppressive TGF and an active immune microenvironment? One possibility is that 
increased immune infiltration precedes the CMS2/CMS4 transition. This would be coherent with the 
notion that cetuximab triggers IgG1 antibody-mediated immunogenic cell death (Pozzi et al., 2016) 
and with the observation that EGFR pathway activity in lung cancer prompts immune escape, which 
is counteracted by EGFR inhibition (Akbay et al., 2013). If this is the case, immune stimulation 
would be a direct consequence of productive cetuximab treatment rather than a hallmark of 
cetuximab resistance, and it would be interesting to see whether cetuximab-sensitive tumors at 
maximal response to EGFR blockade have already undergone the inflammatory shift shown by 
resistant tumors. One could even push this reasoning to the extreme: strengthened TGF activity 
might be a delayed adaptive mechanism to contrast cetuximab-induced immune cell deployment. In 
this scenario, immunotherapy is expected to synergize with cetuximab in the early phases of 
response rather than after the emergence of resistance. 
 The application of genomic technologies has enabled the identification of clinically actionable 
DNA alterations in RAS wild-type mCRC tumors that fail or cease to respond to EGFR antibodies, 
including those illustrated in this study. By providing fresh evidence that acquired resistance to 
cetuximab also entails a stromagenic and immune-inflamed phenotype, results from Woolston et al. 
have important ramifications for the biological understanding of CRC evolution under EGFR 
blockade and introduce potential opportunities for targeting a novel repertoire of non-mutational 
vulnerabilities. 
 
 
 5 
Acknowledgments 
 
L.T. is supported by AIRC, Associazione Italiana per la Ricerca sul Cancro, Investigator Grant 
18532; AIRC 5x1000 grant 21091; AIRC/CRUK/FC AECC Accelerator Award 22795; Transcan, 
TACTIC; European Union H2020 COLOSSUS; Fondazione Piemontese per la Ricerca sul Cancro-
ONLUS, 5x1000 Ministero della Salute 2011, 2014, 2015 and 2016.  
 
 
Declaration of Interests: 
 
L.T. receives research grants from Symphogen, Servier, Pfizer, and Merus, and he is in the 
speakers’ bureau of Eli Lilly, AstraZeneca, and Merck KGaA. 
 
 
Figure legend 
 
Figure 1. The landscape of cetuximab resistance in mCRC, as reported by Woolston et al. (2019). 
New genetic alterations are found to be associated with, and causally responsible for, treatment 
failure in tumors that are or become insensitive to cetuximab therapy. Furthermore, tumors with 
acquired resistance present an abundance of stromal growth factors, which protect cancer cells 
from the antiproliferative effects of EGFR inhibition. Finally, tumors from patients who progress on 
cetuximab are more infiltrated by immune cells and have higher expression levels of immune 
checkpoints than tumors from cetuximab-naïve patients. 
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